ASBP · Aspire Biopharma Holdings, Inc.
$7.76
+0.22 (+2.92%)
At close · Jul 22
Market Cap
$10.05M
Shares
1.30M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$6202
FY2025
Net Income
-$24.48M
-1768.9%
FY2025
Gross Margin
-1.87%
FY2025
Operating Margin
-312016.95%
FY2025
Diluted EPS
-$16.38
-762.1%
FY2025
Operating Cash Flow
-$4.92M
-1756.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | $6202 | — | — | — | |
| — | $6318 | — | — | — | |
| — | -$116 | — | — | — | |
| — | -1.87% | — | — | — | |
| $957.54K | $923.91K | $144.36K | — | — | |
| $904.73K | $789.83K | $126.09K | — | — | |
| $3.58M | $17.64M | $940.42K | $1.34M | $976.35K | |
| $5.45M | $19.35M | $1.21M | $1.34M | $976.35K | |
| — | -$19.35M | -$1.21M | — | — | |
| — | -312016.95% | — | — | — | |
| $9.84M | $8.53M | $97.99K | — | — | |
| — | — | $548.68K | $5.81M | $4.32M | |
| -$6.32M | -$5.13M | -$97.99K | $5.8M | $4.32M | |
| — | -$24.48M | -$1.31M | — | — | |
| — | — | $1013 | — | — | |
| -$11.76M | -$24.48M | -$1.31M | $4.46M | $3.34M | |
| — | -394725.06% | — | — | — | |
| USD/shares | — | -$16.38 | -$1.90 | — | — |
| shares | — | 1.49M | 689.91K | — | — |
| shares | — | 1.49M | 689.91K | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $298.7M in buybacks.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 |
|---|---|
| United States | $6,153 |
| Canada | $30 |
| United Kingdom | $19 |
By Product & Service (USD)
| Component | FY2025 |
|---|---|
| Nutraceutical Products | $6,202 |